January 28, 2015 4:34 AM ET

Biotechnology

Company Overview of Micromet, Inc.

Company Overview

Micromet, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE antibody platform, as well as conventional monoclonal antibodies. The company’s lead product candidate blinatumomab, which is in Phase II clinical trials for the treatment of patients with acute lymphoblastic leukemia, as well as in Phase I clinical trials for the treatment of patients with non-Hodgkin’s lymphomas. It is also developing a BiTE antibody adecatumumab, which is in Phase II clinical trials; and MT110 and MT111, which are in P...

9201 Corporate Boulevard

Suite 400

Rockville, MD 20850

United States

215 Employees

Phone:

240-752-1420

Fax:

302-636-5454

Key Executives for Micromet, Inc.

Chief Financial Officer
Age: 56
Senior Vice President
Age: 61
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
Differential Proteomics, Inc. United States
Maven Biotechnologies, LLC United States
LeadScope, Inc. United States
Laser Pharma Inc. United States
PharmaIN Corporation United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Micromet, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.